Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587649 · ClinicalTrials.gov registry record · Phase 1
Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss
A Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03587649: Completed Phase 1 study, sponsored by Invicro.
NCT03587649 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03587649, a Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The primary objective of this protocol is to examine \[18F\]MNI-1126 as a tool to assess synaptic density loss.
Primary Outcome
Descriptive statistics will be applied to describe the tau deposition by region as measured by \[18F\]MNI-1126.
Interventions
- DRUG [18F]MNI-1126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2020-02-26 |
| Phase | Phase 1 |
What the finished NCT03587649 record still lists
NCT03587649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-1126 is the first listed.
NCT03587649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03587649 about?
NCT03587649 is a clinical study titled "Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss". The primary objective of this protocol is to examine \[18F\]MNI-1126 as a tool to assess synaptic density loss.
What is the current status of trial NCT03587649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-05-07. Estimated completion is 2020-02-26.
What interventions are being tested in trial NCT03587649?
The interventions under investigation include: [18F]MNI-1126 (DRUG).
Who is sponsoring clinical trial NCT03587649?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03587649's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI